MX2021005588A - Composiciones inmunogenicas para el tratamiento de la hepatitis b. - Google Patents
Composiciones inmunogenicas para el tratamiento de la hepatitis b.Info
- Publication number
- MX2021005588A MX2021005588A MX2021005588A MX2021005588A MX2021005588A MX 2021005588 A MX2021005588 A MX 2021005588A MX 2021005588 A MX2021005588 A MX 2021005588A MX 2021005588 A MX2021005588 A MX 2021005588A MX 2021005588 A MX2021005588 A MX 2021005588A
- Authority
- MX
- Mexico
- Prior art keywords
- hepatitis
- treatment
- immunogenic compositions
- hbsag
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760439P | 2018-11-13 | 2018-11-13 | |
| PCT/IB2019/001230 WO2020099927A1 (en) | 2018-11-13 | 2019-11-13 | Immunogenic compositions for treatment of hepatitis b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005588A true MX2021005588A (es) | 2021-08-11 |
Family
ID=70731781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005588A MX2021005588A (es) | 2018-11-13 | 2019-11-13 | Composiciones inmunogenicas para el tratamiento de la hepatitis b. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12128100B2 (enExample) |
| EP (1) | EP3880244A4 (enExample) |
| JP (2) | JP2022513001A (enExample) |
| KR (1) | KR102943479B1 (enExample) |
| CN (2) | CN113423423B (enExample) |
| BR (1) | BR112021009234A2 (enExample) |
| IL (2) | IL283039B2 (enExample) |
| MX (1) | MX2021005588A (enExample) |
| WO (1) | WO2020099927A1 (enExample) |
| ZA (1) | ZA202103976B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022513001A (ja) * | 2018-11-13 | 2022-02-07 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | Ｂ型肝炎の治療のための免疫原性組成物 |
| WO2020254878A1 (en) * | 2019-06-21 | 2020-12-24 | Variation Biotechnologies Inc. | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b. |
| WO2024263918A2 (en) | 2023-06-23 | 2024-12-26 | Brii Biosciences, Inc. | Assessment and treatment of chronic hepatitis b |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242812A (en) | 1989-02-07 | 1993-09-07 | Bio-Technology General Corp. | Method for production and purification of hepatitis B vaccine |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| GB9809507D0 (en) * | 1998-05-01 | 1998-07-01 | Smithkline Beecham Biolog | Novel composition |
| CN1305527C (zh) | 2003-11-21 | 2007-03-21 | 薛平 | 乙型肝炎治疗疫苗及其制备方法 |
| KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| CN102949717A (zh) | 2012-07-06 | 2013-03-06 | 中国疾病预防控制中心病毒病预防控制所 | 一种含poly I:C佐剂的新型乙肝疫苗制剂 |
| CN104043120B (zh) | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
| WO2018166298A1 (en) | 2017-03-13 | 2018-09-20 | Fudan University | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use |
| JP2022513001A (ja) | 2018-11-13 | 2022-02-07 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | Ｂ型肝炎の治療のための免疫原性組成物 |
| WO2020254878A1 (en) | 2019-06-21 | 2020-12-24 | Variation Biotechnologies Inc. | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b. |
-
2019
- 2019-11-13 JP JP2021525603A patent/JP2022513001A/ja active Pending
- 2019-11-13 EP EP19885196.6A patent/EP3880244A4/en active Pending
- 2019-11-13 IL IL283039A patent/IL283039B2/en unknown
- 2019-11-13 CN CN201980074891.6A patent/CN113423423B/zh active Active
- 2019-11-13 CN CN202410981157.0A patent/CN118987191A/zh active Pending
- 2019-11-13 MX MX2021005588A patent/MX2021005588A/es unknown
- 2019-11-13 US US17/293,431 patent/US12128100B2/en active Active
- 2019-11-13 WO PCT/IB2019/001230 patent/WO2020099927A1/en not_active Ceased
- 2019-11-13 BR BR112021009234-0A patent/BR112021009234A2/pt unknown
- 2019-11-13 IL IL314712A patent/IL314712A/en unknown
- 2019-11-13 KR KR1020217018153A patent/KR102943479B1/ko active Active
-
2021
- 2021-06-09 ZA ZA2021/03976A patent/ZA202103976B/en unknown
-
2024
- 2024-09-11 JP JP2024157339A patent/JP2024174990A/ja active Pending
- 2024-09-12 US US18/883,612 patent/US20250269013A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL283039B2 (en) | 2025-01-01 |
| EP3880244A1 (en) | 2021-09-22 |
| US20230079703A1 (en) | 2023-03-16 |
| JP2022513001A (ja) | 2022-02-07 |
| US20250269013A1 (en) | 2025-08-28 |
| EP3880244A4 (en) | 2022-08-17 |
| IL283039B1 (en) | 2024-09-01 |
| KR102943479B1 (ko) | 2026-03-27 |
| BR112021009234A2 (pt) | 2021-09-08 |
| JP2024174990A (ja) | 2024-12-17 |
| CA3119581A1 (en) | 2020-05-22 |
| IL314712A (en) | 2024-10-01 |
| CN118987191A (zh) | 2024-11-22 |
| US12128100B2 (en) | 2024-10-29 |
| KR20210151047A (ko) | 2021-12-13 |
| CN113423423A (zh) | 2021-09-21 |
| CN113423423B (zh) | 2024-08-13 |
| WO2020099927A1 (en) | 2020-05-22 |
| IL283039A (en) | 2021-06-30 |
| ZA202103976B (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500954A1 (en) | Vaccine against porcine parvovirus | |
| EA202092808A1 (ru) | Вакцины на основе наночастиц с новыми структурными компонентами | |
| EA202191736A1 (ru) | Комбинированная терапия hbv | |
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| ZA202104213B (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
| EA201890874A1 (ru) | Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение | |
| EE200100203A (et) | Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon | |
| MX2019004779A (es) | Composicion farmaceutica para tratamiento y/o prevencion de cancer. | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| EA201500114A1 (ru) | Композиция антитела для предупреждения или лечения инфекции мутантным вирусом гепатита b | |
| MX2021005248A (es) | Anticuerpos contra cd73 activadores de células b. | |
| EA202090063A1 (ru) | Композиции и способы для лечения таупатий | |
| EA201591663A1 (ru) | Бесклеточная противококлюшная вакцина | |
| EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
| MD4890B1 (ro) | Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia | |
| EA201892212A1 (ru) | Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b | |
| MX2023009447A (es) | Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos. | |
| EA201892179A1 (ru) | ВАКЦИНА ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА B НА ОСНОВЕ ИНАКТИВИРОВАННЫХ ЦЕЛЬНЫХ РЕКОМБИНАНТНЫХ КЛЕТОК HANSENULA POLYMORPHA, КОТОРЫЕ ЭКСПРЕССИРУЮТ HBsAg | |
| WO2020254878A8 (en) | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b. | |
| MX2021011913A (es) | Composiciones de virus inactivado y formulaciones de vacunas contra el zika. | |
| JP2022513001A5 (enExample) | ||
| AR117191A1 (es) | Composiciones inmunogénicas | |
| MY184876A (en) | Pharmaceutical composition for preventing cccdna formation of hepatitis b virus |